Novel cellular therapies to address T cell malignancies

MediSix Therapeutics is pioneering advancements in T-cell therapies aimed at transforming the treatment landscape for cancer and autoimmune diseases. Central to their approach is the proprietary PEBL (Protein Expression BLocker) technology, which addresses significant challenges associated with CAR T-cell therapies, particularly in T-cell malignancies. PEBL functions by preventing the expression of specific surface proteins on T-cells, thereby enhancing their anti-cancer activity and mitigating issues such as fratricide, where CAR T-cells inadvertently attack each other due to shared target antigens. This innovative method allows for the engineering of CAR T-cells that lack critical T-cell antigens, improving their efficacy against various malignancies while also facilitating the development of allogeneic therapies that minimize the risk of graft-versus-host disease.

In addition to PEBL, MediSix employs a range of tools, including endonucleases, TALEN, and CRISPR/Cas systems, to further enhance T-cell function. Their pipeline includes programs targeting hematologic malignancies and autoimmune diseases, with a focus on developing next-generation CAR T-cell therapies. The integration of PEBL technology streamlines the manufacturing process, reduces the risk of product contamination, and improves cell viability, making it a promising solution for patients with complex T-cell malignancies. Overall, MediSix Therapeutics is committed to leveraging these advanced technologies to create effective and safe therapeutic options for patients facing challenging health conditions.

Singapore

MediSix Therapeutics - We are a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. Our technology platform originates from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. Our programs utilize proprietary immune engineering approaches that enable T cell leukemias and lymphomas to be targeted with cell therapy.

MediSix Therapeutics

Company Details